Exchange: NASDAQ·Updated 07:30 PM EST
AUTL logo

AUTL Autolus Therapeutics Ltd - ADR

$0.92
$0.0723
(7.38%)
Today
Closed $0.9073
$0.0127
(1.40%)
After Hours
Reported EarningsNov 10
Mkt Cap$241.65M
Vol3.9M

About AUTL

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
61

Bullish Sentiment

How do you feel about AUTL?

js3456
$AUTL I am also holding massive bags at $2…full disclosure. wish i could buy at these levels. nonetheless, still bullish in the short to medium terms (2-4 yrs)
9
LogoA12
$AUTL Some may find it unfair how low Autolus (and CAR-T in general) is valued right now. Still, the science works. Yes, it may be a bit pricey for the future, and in vivo and off-the-shelf are real competition. But in my view it's a solid, well-built company. I've followed its data and structure for years and think Autolus is very well positioned. Remember: this is a treatment for seriously ill patients, and physicians decide what works best for them. Scaling isn't like selling sneakers. Each dose is made individually for one patient, so it takes time, and it should. If you expect a rally in the next 1-2 months or even 12, put your money elsewhere. It's a volatile small-cap biotech, exposed to big-money moves. But the story holds up, and I'm staying long. Just my opinion, not financial advice. DYOR.
12
Liberio
$AUTL Honestly, I don’t really get these posts, and I have no idea how management is supposed to just magically speed up revenue growth. IMO, everything is moving forward nicely. Revenue is right on track, and R&D isn't pointless cash burn—it’s building real long-term value. This isn't fast food where you just throw extra onions into a burger to boost sales. Patients aren't consumer staples.
2
6
cowneck_trader
$AUTL MAJOR LUPUS DATA UPDATE! 🔥 ACR 2026 CARLYSLE Phase 1 results: • 15 patients infused, up from 12 • 100% DORIS remission in patients with ≥6 months follow-up • 67% complete renal response (6/9) • Maximum follow-up now 25.5 months • ZERO severe CRS or ICANS • ZERO severe renal flares • B-cell recovery predominantly naïve/transitional 💎 Potential immune reset after ONE infusion rather than lifelong immunosuppression. ✅ FDA RMAT designation ✅ Pivotal Phase 2 LUMINA enrolling ✅ Approved AUCATZYL commercial platform Deepening evidence of durable efficacy with favorable safety. $AUTL 's autoimmune opportunity is getting harder to ignore.
13
BRLondon
$AUTL Beating the top end of their guidance and all financial metrics tending in the right direction. Great execution.
13
medinapj
$AUTL Locked and loaded, added a bunch more in my rollover at $1.29. Hopefully, a good day tomorrow. Good luck all longs (not many of us on here) 🍀🤞🍀🤞
13
Stockman159
$AUTL So let me get this straight, good ER, good data release on the same day and the stock price goes down. Nice makes total sense. It doesn't matter what analyst are rating a year from now if positive catalysts do nothing.
1
9
BRLondon
$AUTL These are amazing results. Safety and efficacy. Market will catch on. Bids may take some time but no one will be selling into lower levels with these data.
12
Kai_01
$AUTL Sharing some thoughts for everyone to challenge/contribute to. Summarising: AUTL is a British FDA approved CAR-T company with operations in US and UK, and as such has two main catalyst types: 1. Commercial validation of the approved AUCATZYL 2. Clinical pipeline related catalysts. It is important to note that unlike other companies who choose to only dilute and not sign partnerships, AUTL has several royalty-related financial obligations and expensive secured financial agreement (Perceptive Advisors is behind it). The pipeline which is relatively early stage, but very abundant and offering several catalysts short term (2026 - 27H2). One of AUTL's clinical strenghts is CD19 binding, which usually translates into:
12
Kosmokrat
$AUTL I am very happy I picked up a decent lot @$1.21. Autolus is still growing double digits. They are just starting to roll out of AUCATZYL internationally. I really like their pipeline. If only a fraction of their pipeline materializes, we'll have a multi-billion-$ company. Well, that's still a few years out. Their current valuation is a joke. I think $200M revenue in 2027 is doable, which should justify a $800M market cap. Maybe a bit less, because they won't be profitable before 2029 or so. But I do expect the SP to reach $2.50 next year. Double from where it is now. They won't need any diluting capital injection, either they become cash flow positive before cash runs out, or they take on some credit or strike a partnership with upfront payments.
11
Biotechs5454
$AUTL Don’t mark this post but calling the bottom on this one last Friday 10/30. Added more $1.50. 💨💨💨🤞🤞🤞🙏🙏🙏
11
Michael_garic
$AUTL here is the same chart with volume. We can now see the large volume of sales right after the Q2 2025 earnings announcement and during September 2025 as the stock price tanked. This is Wellington selling their 27M or 10% stake in AUTL as reported in their Q2 2025 13F.
1
8
resume777
$AUTL Gilead earnings: Tecartus's U.S. revenue is now down 40% year over year, compared with 29% in Q2. In today's Q3 release, the company describes the overall cell-therapy decline as reflecting ongoing competitive headwinds.
11
BRLondon
$AUTL I thought we saw the lows on ER day before the data release. I was wrong. Nevertheless this is where the brave buy and make the millions. This company is going to make around $250 million in sales next year and Lupus readout in H1 2028 is not that far away. Bargain prices. This could be a 4B market cap in a few years as someone below said. Bought more at 0.9751 today.
8
dgbio
$AUTL Just to remind what is next for Autolus beyond growing the US/UK sales: • I expect to hear about the European launch soon. With tariffs no longer a threat, and the US price stable, I expect Autolus will start negotiating in Germany, at least. Under the current MFN rules they can offer a discount of up to 30% based on the GDP adjustment. Tecartus sells in Germany for about $300K after discounts. With a bit of premium for higher safety, Aucatzyl will fit right in. Europe can't ignore the dominant player in the US/UK market. • Consolidation therapy trial run by M. D. Anderson is running. If successful it will expand the addressable market at least 2x. • The pediatric trial is very likely to succeed and it will add the significant market as well. • And then we have LN and PrMS trials – a focused approach to immunology, indications where moderate safety issues, real or perceived, are unlikely to derail the programs and the endpoints are well-defined and objective.
9
Michael_garic
$AUTL My take on the stock drop: Revenue fell from Q2-$41.2M versus $45.7M is the first sequential drop since the jump in Q2, and no real forecast that Q4 will improve on Q3. The only word we got was more centers and physician awareness. The guidance raise was modest - At or above $150M" only implies a Q4 of about $37M, below Q3. Some investors may read it as another soft quarter rather than a raise. The MS data slipped a year- to the second half of 2027. That pushes out a potential upside story. Although this was explained as changing guideline/requirements. The EPS headlines say "miss." Seeking Alpha and Benzinga framed EPS as a 3-cent miss against a −$0.18 estimate, and headline-driven trading tends to sell first. Debt costs are rising. The $12M in other expenses, reminds investors that the cash runway is partly borrowed. That being said the company still has the best in class CAR T B ALL treatment. The question has always been, can they make money?
10
Michael_garic
$AUTL 8:30 call...need answers A real number for 2026 "At or above $150M" is vague. Something like "$155M+", Q4 is running ahead of Q3.. Q3 dipped- If they say the drop from $45.7M was a one-time Q2 boost (the extra registrations after the TANDEM data) and that demand is growing again in Q4, that removes the main worry. An updated center count, ideally on track for the 90+ they promised, plus more patients per center, since they credited growth within existing centers. Any early 2027 revenue target or growth expectation, which they haven't given yet. Margins/ path to breakeven- Gross margin heading toward 60%, or a timeline for being cash-flow positive, especially now that they're paying interest on the Perceptive debt. Lupus- Encouraging data from today's CARLYSLE poster, or clearer LUMINA timing, would strengthen the bigger long-term story. Reassurance on MS-Framing the MS delay as a deliberate choice, not a weak signal, would help limit any damage. EU Plan/expansion
10
XX1XX
$AUTL the decline has nothing to do with AUTL, nothing has changed other than positive things. just look at the chart of any small cap bio and the charts almost all look identical. this is all about rates going up which is a sell for bios. there is no leak there is catalyst for the decline, just simply algos doing what they are programmed to do which sell and short bios when rates are moving up.
1
7
Bigjohnson99
$AUTL started a position here today. 30k share at $1.28. I’ll add more Monday on any weakness. Tuesday may see a solid re-rating.
9
Flying_Trader2
$AUTL Brutal, I must say I really thought we were done with the 1.40’s let alone the 1.30’s.
9

Advertisement|Remove ads.